Could a constipation drug help fight colorectal cancer?

NCT ID NCT03796884

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This Phase 2 trial is testing whether linaclotide, a drug currently used for constipation, can slow or prevent colorectal cancer growth. About 150 people with colorectal polyps or early-stage cancer will take the drug or a placebo before surgery. Researchers will measure changes in cell signals and tumor markers to see if the drug has a biological effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
linaclotide
What this could lead to
If it works, this could point toward a new way to slow or prevent colorectal cancer growth using a drug already approved for other conditions.
What could go wrong
This is an early Phase 2 trial with only 150 participants, so results may not apply broadly. The drug may not show enough effect on tumor markers to justify larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

    Philadelphia, Pennsylvania, 19126, United States

  • VA Puget Sound Health Care Sysem

    Seattle, Washington, 98108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.